Porter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012, 14:830. ten. Seman L, Macha S, Nehmiz G, Simons G, Ren B, Pinnetti S, Woerle HJ, Dugi KA: Empagliflozin (BI 10773), a potent and selective SGLT-2 inhibitor, induces dose-dependent glucosuria in healthful subjects. Clinical Pharm in Drug Dev 2013. doi:10.1002/cpdd.16 [Epub ahead of print]. 11. Cubeddu LX: QT prolongation and fatal arrhythmias: A evaluation of clinical implications and effects of drugs. Am J Ther 2003, ten:45257. 12. European Medicines Agency: ICH subject E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic possible for non-antiarrhythmic drugs: Step 5: Note for guidance on the clinical evaluation of QT/QTc interval prolongation and proarrhythmic prospective for nonantiarrhythmic drugs. 2005. November 2005, CHMP/ICH/2/04. Readily available from http://www.ema.europa.eu. Accessed 26 March 2012. 13. van Noord C, Eijgelsheim M, Stricker BH: Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010, 70:163. 14. Preis SR, Hwang SJ, Coady S, Pencina MJ, D’Agostino RB Sr, Savage PJ, Levy D, Fox CS: Trends in all-cause and cardiovascular illness mortalityRing et al. Cardiovascular Diabetology 2013, 12:70 http://www.cardiab/content/12/1/Page 11 of15.16. 17. 18. 19. 20. 21. 22. 23. 30.31.32. 33.34.35. 36. 37. 38.39. 40. 41.among ladies and men with and with out diabetes mellitus within the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119(13):1728735. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di AE, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, et al: Diabetes mellitus, fasting blood glucose concentration, and threat of vascular disease: a collaborative meta-analysis of 102 potential studies. Lancet 2010, 375:2215222. DeSouza CV, Fonseca V: Therapeutic targets to minimize cardiovascular disease in sort 2 diabetes.Osanetant Cancer Nat Rev Drug Discov 2009, eight:36167. DeSouza CV, Bolli GB, Fonseca V: Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010, 33:1389394. WHO: World Well being Organization Diabetes factsheet. 2011. Accessible from http:// www.who.int/mediacentre/factsheets/fs312/en/. Accessed 26 March 2012. DeFronzo RA: Overview of newer agents: Where therapy is going. Am J Med 2010, 123:S38 48. Ovalle F: Cardiovascular implications of antihyperglycemic therapies for sort two diabetes. Clin Ther 2011, 33:39307. Chanter DO: Extra power for your cash. Prague: Drug Details Association Cardiac Security Conference; 2007.Eact Technical Information Ring A, Walter B, Larbalestier A, Chanter D: An effective cross-over style for thorough QT studies.PMID:25016614 GMS Med Inform Biom Epidemiol 2010, six:Doc05. Julious SA: Seven useful designs. Pharm Stat 2012, 11:241. Meals and Drug Administration: International conference on harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic possible for non-antiarrhythmic drugs. Fed Regist 2005, 70:611341135. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, Gottesdiener K, Wagner JA: The effect of moxifloxacin on QTc and implications for the style of thorough QT research. Clin Pharmacol Ther 2008, 84:47580. Morganroth J, Ilson BE, Shaddinger BC, Dabiri GA, Patel BR, Boyle DA, Sethuraman VS, Montague TH: Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol 2004, 93:13783. A6. Extramiana F, Maison-Blanche P, Cabanis MJ, Ortemann-Renon C, Beaufils P, Leenhardt A: Clinical asses.